MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 2

Conditions

Alzheimer's Disease

Treatments

Drug: MK0952

Drug: Comparator: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00362024

2006_026

0952-004

Details and patient eligibility

About

MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.

Enrollment

24 patients

Sex

All

Ages

55+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or females
Age >/= 55 years, With mild-to-moderate AD, with MMSE between 18 and 26, inclusive, MHIS score </= 4, Global CDR score of 1 or 2
Who have a reliable informant/caregiver to accompany patient to all clinic visits
If using a symptomatic AD treatments, patients must be on stable dose for >/= 6 months

Exclusion criteria

Patients must not be living in nursing home or skilled nursing facility
Patients must not have current evidence and/or history of Crohn's disease, ulcerative colitis, proctitis, GI bleeding, mesenteric arteritis
Patients must not have current evidence and/or history of poorly-controlled hypertension, clinically significant cardiac arrhythmia, angina, or CHF
Patients must not have current evidence and/or history of a psychotic disorder or major untreated depressive disorder
Patients must not have current evidence and/or history of stroke or multiple lacunar infarcts, or neurological or neurodegenerative disorder (other than AD)
Various concomitant therapy restrictions